Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

Observation of Long Term Effect of Medical and PTPA Treatment on Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05388682

Enrollment

200

Registered

2022-05-24

Start date

2014-01-19

Completion date

2042-12-31

Last updated

2023-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PAH Targeted Medication, Percutaneous Transluminal Pulmonary Angioplasty, Takayasu Arteritis With Pulmonary Artery Involvement

Keywords

Percutaneous transluminal pulmonary angioplasty, Takayasu Arteritis with Pulmonary Artery Involvement

Brief summary

1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement

Detailed description

At baseline, FAPI and FDG are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. FAPI is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.

Interventions

DEVICEPercutaneous transluminal pulmonary angioplasty

Percutaneous transluminal pulmonary angioplasty

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients diagnosed with Takayasu arteries with pulmonary arteries involvement

Exclusion criteria

* Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis

Design outcomes

Primary

Measure	Time frame	Description
all cause death	2014/1/1-2042/12/31	all cause death
mean pulmonary arterial pressure change	2014/1/1-2042/12/31	change of mean pulmonary arterial pressure after treatment
pulmonary vascular resistance change	2014/1/1-2042/12/31	chagne of pulmonary vascular resistance after treatment
6MWD change	2014/1/1-2042/12/31	change of six minute walk distance after treatment
peak VO2 change	2014/1/1-2042/12/31	change of peak oxygen consumption after treatment
NT-proBNP change	2014/1/1-2042/12/31	change of NT-proBNP after treatment
RV/LV change	2014/1/1-2042/12/31	change of right ventricular end-diastolic diameter versus laboratory left ventricular end-diastolic diameterafter treatment
CI change	2014/1/1-2042/12/31	change of cardiac index after treatment

Countries

China

Contacts

Primary ContactZhihong Liu, doctor

zhihongliufuwai@163.com86-010-88396589

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026